Semaglutide is a new GLP-1 analog for the once-weekly treatment of T2D. This post-hoc analysis assessed the effect of semaglutide on renal function by baseline eGFR in the SUSTAIN 6 trial.
Overall, mean eGFR decreased from baseline to week 104 across all treatment groups and subgroups, with the largest decreases in subjects with normal renal function or mild renal impairment. Urine albumin-to-creatinine ratio decreased with increasing renal impairment for semaglutide 1.0 mg, but not other treatment groups (Table). AEs related to acute renal failure were generally higher with increasing baseline renal impairment, except with semaglutide 1.0 mg vs. placebo. New or worsening nephropathy was lower with both doses of semaglutide vs. placebo.